SynCardia implants Emperor Total Artificial Heart in first in vivo study

Picard Medical, Inc.

Three pre-clinical models successfully implanted with the Emperor TAH; all taken off bypass without issues.
Device provided full, stable blood circulation with efficient energy use and no technical problems.
Emperor TAH exhibited Frank-Starling response: natural pump output adjustment based on blood volume.
Results consistent with Picard Medical's laboratory performance goals; program acceleration expected.
Emperor platform designed as a fully implantable successor to the FDA-approved SynCardia TAH.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.